T1	PROC 46 105	Estudio para evaluar la seguridad, tolerabilidad y eficacia
T2	PROC 239 282	Ensayo aleatorizado, abierto, multicéntrico
T3	PROC 288 307	evaluar la eficacia
#1	AnnotatorNotes T3	C1707887; Efficacy Study; Research Activity
T4	CHEM 311 322	secukinumab
#2	AnnotatorNotes T4	C3179547; secukinumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T5	PROC 361 372	tratamiento
#3	AnnotatorNotes T5	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T6	PROC 375 421	evaluar la seguridad, tolerabilidad y eficacia
T7	DISO 580 624	áreas rojas, elevadas y escamosas de la piel
T8	DISO 559 568	psoriasis
#4	AnnotatorNotes T8	C0033860; Psoriasis; Disease or Syndrome
T9	ANAT 604 613	escamosas
#5	AnnotatorNotes T9	C0221909; Squamous epithelium; Tissue
T10	ANAT 620 624	piel
#6	AnnotatorNotes T10	C1123023; Skin; Body System | C1278993; Entire skin; Body System
T11	DISO 651 670	Psoriasis en placas
#7	AnnotatorNotes T11	C0263361; Psoriasis vulgaris; Disease or Syndrome
T12	PROC 852 862	evaluación
#8	AnnotatorNotes T12	C1261322; Evaluation procedure; Health Care Activity
T13	PROC 931 945	aleatorización
#9	AnnotatorNotes T13	C0034656; Randomization; Research Activity
T14	DISO 950 969	Psoriasis en placas
#10	AnnotatorNotes T14	C0263361; Psoriasis vulgaris; Disease or Syndrome
T15	ANAT 1068 1071	ASC
#11	AnnotatorNotes T15	C4512722; Body surface area; Body Location or Region
T16	DISO 1099 1118	psoriasis en placas
#12	AnnotatorNotes T16	C0263361; Psoriasis vulgaris; Disease or Syndrome
T17	PROC 1156 1170	aleatorización
#13	AnnotatorNotes T17	C0034656; Randomization; Research Activity
T18	PROC 1231 1252	tratamiento sistémico
T19	DISO 1350 1359	psoriasis
#14	AnnotatorNotes T19	C0033860; Psoriasis; Disease or Syndrome
T20	DISO 1366 1393	psoriasis crónica en placas
T21	PROC 1407 1421	aleatorización
#15	AnnotatorNotes T21	C0034656; Randomization; Research Activity
T22	DISO 1426 1435	Psoriasis
#16	AnnotatorNotes T22	C0033860; Psoriasis; Disease or Syndrome
T23	CHEM 1449 1457	fármacos
#17	AnnotatorNotes T23	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T24	PROC 1475 1487	tratamientos
#18	AnnotatorNotes T24	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T25	PROC 1645 1668	métodos anticonceptivos
#19	AnnotatorNotes T25	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T26	PROC 1750 1776	suspensión del tratamiento
#20	AnnotatorNotes T26	C0850893; stop medication; Therapeutic or Preventive Procedure
T27	ANAT 1875 1885	leucocitos
#21	AnnotatorNotes T27	C0023516; Leukocytes; Cell
T28	PROC 1897 1906	plaquetas
#22	AnnotatorNotes T28	C0032181; Platelet Count measurement; Laboratory Procedure
T29	PROC 1921 1932	neutrófilos
#23	AnnotatorNotes T29	C0200633; Neutrophil count; Laboratory Procedure
T30	PROC 1857 1885	recuento total de leucocitos
T31	CHEM 2006 2017	secukinumab
#24	AnnotatorNotes T31	C3179547; secukinumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T32	CHEM 2037 2054	fármaco biológico
#25	AnnotatorNotes T32	C0005515; Biological Factors; Biologically Active Substance (?)
T33	CHEM 2084 2090	IL-17A
T34	DISO 169 196	psoriasis crónica en placas
T35	DISO 485 512	psoriasis crónica en placas
T36	PROC 700 734	Asentimiento informado por escrito
#26	AnnotatorNotes T36	C0811741; Obtain informed written consent; Health Care Activity
T37	PROC 1689 1703	administración
#27	AnnotatorNotes T37	C1533734; Administration procedure; Therapeutic or Preventive Procedure
T38	PROC 1944 1955	hemoglobina
#28	AnnotatorNotes T38	C0518015; Hemoglobin measurement; Laboratory Procedure
T39	CHEM 2096 2113	receptor de IL-17
T40	Date 13 17	2017
T41	Date 106 119	a largo plazo
T42	LIVB 123 132	pacientes
#29	AnnotatorNotes T42	C0030705; Patients; Patient or Disabled Group
T43	Age 133 156	de 6 a menos de 18 años
T44	Duration 179 186	crónica
#30	AnnotatorNotes T44	C0205191; chronic; Temporal Concept
T45	Route 323 333	subcutáneo
T46	Duration 345 357	doce semanas
T47	Date 422 435	a largo plazo
T48	LIVB 439 448	pacientes
#31	AnnotatorNotes T48	C0030705; Patients; Patient or Disabled Group
T49	Age 449 472	de 6 a menos de 18 años
T50	Duration 495 502	crónica
#32	AnnotatorNotes T50	C0205191; chronic; Temporal Concept
T52	LIVB 757 769	progenitores
#33	AnnotatorNotes T52	C0030551; parent; Family Group | C0870134; Ancestor; Family Group
T54	Age 879 902	de 6 a menos de 18 años
T55	Duration 1127 1143	al menos 3 meses
T56	LIVB 1175 1184	Pacientes
#34	AnnotatorNotes T56	C0030705; Patients; Patient or Disabled Group
T57	LIVB 1192 1204	investigador
#35	AnnotatorNotes T57	C0035173; Research Personnel; Professional or Occupational Group
T58	LIVB 1279 1288	pacientes
#36	AnnotatorNotes T58	C0030705; Patients; Patient or Disabled Group
T59	Duration 1376 1383	crónica
#37	AnnotatorNotes T59	C0205191; chronic; Temporal Concept
T60	Date 1465 1471	actual
T62	LIVB 1502 1534	Pacientes mujeres en edad fértil
#38	AnnotatorNotes T62	C0030705; Patients; Patient or Disabled Group + C4324275; Woman of childbearing potential; Population Group
T63	Age 1523 1534	edad fértil
T65	LIVB 1560 1567	mujeres
#39	AnnotatorNotes T65	C0043210; Woman; Population Group
T67	Duration 1718 1732	las 16 semanas
T69	LIVB 1791 1836	Mujeres embarazadas o en periodo de lactancia
#40	AnnotatorNotes T69	C0033011; Pregnant Women; Population Group | C4316174; Patients who are breastfeeding; Patient or Disabled Group
T70	LIVB 1840 1849	Pacientes
#41	AnnotatorNotes T70	C0030705; Patients; Patient or Disabled Group
T78	PHYS 1568 1616	fisiológicamente capaces de quedarse embarazadas
#42	AnnotatorNotes T78	C3831118; Childbearing Potential; Clinical Attribute
T51	PHYS 1799 1810	embarazadas
#43	AnnotatorNotes T51	C0032961; Pregnancy; Organism Function
T61	PHYS 1827 1836	lactancia
#44	AnnotatorNotes T61	C0006147; Breast Feeding; Organism Function | C0022925; Lactation; Organ or Tissue Function
T64	Neg_cue 1360 1365	salvo
A2	Population_data T62 Age
A4	Assertion T24 Contraindicated
A5	Assertion T20 Negated
A6	Status T31 History_of
A7	Status T32 History_of
A8	Status T16 History_of
#45	AnnotatorNotes T1	C0511730; Identify product efficacy and safety issues; Health Care Activity + C3274448; Tolerability Study; Research Activity
#46	AnnotatorNotes T41	C0443252; Long-term; Temporal Concept
#47	AnnotatorNotes T6	C0511730; Identify product efficacy and safety issues; Health Care Activity + C3274448; Tolerability Study; Research Activity
#48	AnnotatorNotes T47	C0443252; Long-term; Temporal Concept
#49	AnnotatorNotes T30	C0023508; White Blood Cell Count procedure; Laboratory Procedure 
#50	AnnotatorNotes T33	C1701790; IL17A protein, human; Amino Acid, Peptide, or Protein · Biologically Active Substance 
#51	AnnotatorNotes T39	C1721056; Receptors, Interleukin-17; Amino Acid, Peptide, or Protein · Receptor
T53	Quantifier_or_Qualifier 1394 1400	activa
A1	Assertion T53 Negated
#52	AnnotatorNotes T53	C0679217; Active State; Idea or Concept
R1	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T53	
R2	Has_Age Arg1:T42 Arg2:T43	
R3	Experiences Arg1:T42 Arg2:T34	
R4	Has_Duration_or_Interval Arg1:T34 Arg2:T44	
T66	Quantifier_or_Qualifier 200 216	moderada a grave
#53	AnnotatorNotes T66	C1299393; Moderate to severe; Qualitative Concept
R5	Has_Quantifier_or_Qualifier Arg1:T34 Arg2:T66	
T68	Quantifier_or_Qualifier 516 532	moderada a grave
#54	AnnotatorNotes T68	C1299393; Moderate to severe; Qualitative Concept
R6	Has_Quantifier_or_Qualifier Arg1:T35 Arg2:T68	
R7	Has_Duration_or_Interval Arg1:T35 Arg2:T50	
R8	Has_Route_or_Mode Arg1:T4 Arg2:T45	
R9	After Arg1:T4 Arg2:T46	
R10	Has_Duration_or_Interval Arg1:T5 Arg2:T46	
R11	Used_for Arg1:T4 Arg2:T5	
R12	Overlap Arg1:T6 Arg2:T47	
R13	Experiences Arg1:T48 Arg2:T4	
R14	Has_Age Arg1:T48 Arg2:T49	
R15	Experiences Arg1:T48 Arg2:T5	
R16	Experiences Arg1:T48 Arg2:T35	
R17	Location_of Arg1:T10 Arg2:T7	
R18	Causes Arg1:T8 Arg2:T7	
T71	PROC 814 823	selección
#55	AnnotatorNotes T71	C0242802; Patient Selection; Research Activity
R19	Overlap Arg1:T36 Arg2:T71	
R20	Before Arg1:T36 Arg2:T12	
T72	PROC 1972 1981	selección
#56	AnnotatorNotes T72	C0242802; Patient Selection; Research Activity
R21	Overlap Arg1:T13 Arg2:T54	
T73	Result_or_Value 1072 1078	≥ 10 %
T74	CONC 1020 1024	PASI
#57	AnnotatorNotes T74	C4528685; Psoriasis Area and Severity Index Clinical Classification; Intellectual Product
T75	Result_or_Value 1025 1029	≥ 12
R22	Has_Result_or_Value Arg1:T74 Arg2:T75	
T76	Quantifier_or_Qualifier 973 989	moderada a grave
#58	AnnotatorNotes T76	C1299393; Moderate to severe; Qualitative Concept
R23	Has_Quantifier_or_Qualifier Arg1:T14 Arg2:T76	
T77	Observation 1053 1071	afectación del ASC
R24	Has_Result_or_Value Arg1:T77 Arg2:T73	
R25	Location_of Arg1:T15 Arg2:T77	
T79	Date 1041 1045	2011
T80	CONC 1032 1045	IGA mod. 2011
T81	Result_or_Value 1046 1049	≥ 3
R26	Has_Result_or_Value Arg1:T80 Arg2:T81	
R29	Causes Arg1:T14 Arg2:T77	
R30	Has_Duration_or_Interval Arg1:T16 Arg2:T55	
R31	Before Arg1:T16 Arg2:T17	
#59	AnnotatorNotes T18	C1515119; Systemic Therapy; Therapeutic or Preventive Procedure
R32	Experiences Arg1:T56 Arg2:T18	
R33	Negation Arg1:T64 Arg2:T20	
R34	Has_Duration_or_Interval Arg1:T20 Arg2:T59	
R35	Negation Arg1:T64 Arg2:T53	
R37	Overlap Arg1:T20 Arg2:T21	
R38	Causes Arg1:T23 Arg2:T22	
R39	Overlap Arg1:T24 Arg2:T60	
R40	Has_Age Arg1:T62 Arg2:T63	
R41	Experiences Arg1:T65 Arg2:T25	
R42	Overlap Arg1:T25 Arg2:T37	
R43	Has_Duration_or_Interval Arg1:T25 Arg2:T67	
R44	After Arg1:T25 Arg2:T26	
R46	Experiences Arg1:T65 Arg2:T78	
R47	Experiences Arg1:T62 Arg2:T25	
R48	Experiences Arg1:T62 Arg2:T37	
R49	Experiences Arg1:T65 Arg2:T37	
R50	Experiences Arg1:T62 Arg2:T26	
R51	Experiences Arg1:T65 Arg2:T26	
R52	Experiences Arg1:T69 Arg2:T51	
R53	Experiences Arg1:T69 Arg2:T61	
R54	Experiences Arg1:T70 Arg2:T30	
T82	Result_or_Value 1886 1895	< 2500/μl
R55	Has_Result_or_Value Arg1:T30 Arg2:T82	
T83	Result_or_Value 1907 1919	< 100 000/μl
R56	Has_Result_or_Value Arg1:T28 Arg2:T83	
T84	Result_or_Value 1933 1941	<1500/μl
R57	Has_Result_or_Value Arg1:T29 Arg2:T84	
T85	Result_or_Value 1956 1965	<8,5 g/dl
R58	Has_Result_or_Value Arg1:T38 Arg2:T85	
R59	Experiences Arg1:T70 Arg2:T28	
R60	Experiences Arg1:T70 Arg2:T29	
R61	Experiences Arg1:T70 Arg2:T38	
T86	Quantifier_or_Qualifier 2055 2113	directamente dirigido contra IL-17A o el receptor de IL-17
R62	Has_Quantifier_or_Qualifier Arg1:T32 Arg2:T86	
A3	Status T86 History_of
R63	Overlap Arg1:T1 Arg2:T41	
R64	Overlap Arg1:T30 Arg2:T72	
R65	Overlap Arg1:T28 Arg2:T72	
R66	Overlap Arg1:T29 Arg2:T72	
R67	Overlap Arg1:T38 Arg2:T72	
#60	AnnotatorNotes T45	C1522438; Subcutaneous Route of Drug Administration; Functional Concept
R27	Overlap Arg1:T19 Arg2:T21	
T87	Quantifier_or_Qualifier 1669 1677	eficaces
#61	AnnotatorNotes T87	C1704419; Effective; Qualitative Concept
R28	Has_Quantifier_or_Qualifier Arg1:T25 Arg2:T87	
#62	AnnotatorNotes T60	C0521116; Current (present time); Temporal Concept
A9	Experiencer T42 Patient
A10	Experiencer T48 Patient
A11	Experiencer T52 Family_member
A12	Experiencer T57 Other
A13	Experiencer T56 Patient
A14	Experiencer T58 Patient
A15	Experiencer T62 Patient
A16	Experiencer T65 Patient
A17	Experiencer T69 Patient
A18	Experiencer T70 Patient
A19	Status T18 Future
